CS-747S PhaseIII trial (elective PCI)

CS-747S PhaseIII trial -Double-blinded study for evaluation of efficacy and safety of CS-747S in reference to clopidogrel bisulfate in subject with coronary arterial disease who are to undergo elective percutaneous coronary intervention-

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221511

Enrollment

600

Registered

2011-07-12

Start date

2011-07-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAD patients who are to undergo elective PCI

Interventions

investigational material(s) Generic name etc : Prasugrel Hydrochloride INN of investigational material : Prasugrel Therapeutic category code : 339 Other agents relating to blood and body fluides Dosag

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Subjects aged 20 or above when written informed consent were signed by the subjects. -CAD patients with coronary artery stenosis identified by coronary angiography or CT scan, and scheduled for elective PCI.

Exclusion criteria

Exclusion criteria: -High bleeding risk -Subjects with ACS -Liver and/or kidney function impairment

Design outcomes

Primary

Measure	Time frame
Rate of MACE Six months MACE and 95% confidence intervals are to be calculated, and the cumulative event rate are estimated by Kaplan-Meier method.	—

Secondary

Measure	Time frame
The rate of non-CABG bleeding events. The incidence of bleeding events and their 95% confidence intervals are to be calculated.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026